Retension Pharmaceuticals, a clinical-stage biotechnology company developing a treatment for uncontrolled and resistant hypertension, has raised $45 million in an upsized initial public offering, pricing 3.8 million shares at $12 each. The offering priced within the original $11 to $13 range and exceeded the company’s initial plan to sell 3.3 million shares, giving the company a fully diluted market value of approximately $114 million.

IPO Pricing and Nasdaq Listing

Retension Pharmaceuticals priced its IPO at $12 per share, the midpoint of its proposed range. By increasing the offering from 3.3 million to 3.8 million shares, the company expanded the transaction while maintaining its original pricing range.

The company will trade on the Nasdaq under the symbol RTSN. Leerink Partners, Guggenheim Securities and Oppenheimer & Co. acted as joint bookrunners for the offering.

RTN-001 Targets Uncontrolled Hypertension

Retension Pharmaceuticals is developing a single lead asset, RTN-001, a once-daily oral phosphodiesterase-5 (PDE5) inhibitor intended to treat uncontrolled and resistant hypertension.

According to the company, earlier-generation PDE5 inhibitors, including Viagra, did not produce meaningful blood pressure reductions because of limited penetration into the smooth-muscle-rich central vasculature. RTN-001 was re-engineered to improve bioavailability and increase distribution into those tissues.

The approach is designed to address a treatment challenge in patients whose blood pressure remains inadequately controlled, although RTN-001’s efficacy and safety still need to be established through clinical development.

Drug Development History and Clinical Trial Progress

RTN-001 was originally developed at Surface Logix and subsequently passed through Nano Terra, Kadmon and Sanofi before the current team relicensed the compound in 2023.

The asset brought a development history that includes nine completed clinical trials, including two Phase 2 pilot studies.

A 280-patient Phase 2b dose-ranging trial began in October 2025 and was approximately 40% enrolled at the time described in the company’s IPO information. Initial data are expected in the first half of 2027.

The upcoming results could provide a more detailed assessment of the drug’s potential across different doses and its ability to reduce blood pressure in patients with uncontrolled or resistant hypertension.

Company Background and IPO Proceeds

Retension Pharmaceuticals is based in Falls Church, Virginia. Its IPO raised $45 million through the sale of 3.8 million shares at $12 each, with the company entering the public markets at a fully diluted valuation of approximately $114 million.

The available offering information does not specify how the proceeds will be allocated across clinical development, operating expenses or other corporate priorities.

Market Context & Opportunities

Hypertension remains a major therapeutic area, and treatments for patients whose blood pressure is difficult to control represent a potential opportunity for pharmaceutical developers. Retension’s focus on a once-daily oral therapy and its effort to improve drug distribution into central vascular tissues differentiate the stated rationale behind RTN-001.

The company’s clinical history provides a foundation for further investigation, while the Phase 2b trial represents an important upcoming milestone. The expected 2027 data could help investors assess whether the compound’s design translates into meaningful clinical results.

Risks & Challenges

Retension remains a clinical-stage biotechnology company whose investment outlook depends heavily on the development of a single lead asset. Earlier trial experience does not guarantee that RTN-001 will demonstrate sufficient safety or efficacy in a larger Phase 2b study.

The trial is still ongoing, with initial data not expected until the first half of 2027. Clinical setbacks, delays or results that do not support further development could materially affect the company’s prospects.

The IPO valuation also reflects expectations about future development rather than an established commercial product, making clinical outcomes and the company’s ability to fund subsequent trials important considerations.

Closing Paragraph

Retension Pharmaceuticals has raised $45 million through an upsized Nasdaq IPO, providing a public-market platform for advancing RTN-001, its investigational once-daily oral treatment for uncontrolled and resistant hypertension. With its 280-patient Phase 2b trial underway and initial data expected in the first half of 2027, the company’s next major milestone will be demonstrating whether its redesigned PDE5 inhibitor can deliver meaningful clinical benefits.